Epigenx Pharmaceuticals

Santa Barbara, CA 93111

SBIR Award Summary

Total Number of Awards 12
Total Value of Awards $2.41MM
First Award Date 03/15/01
Most Recent Award Date 09/07/04

Key Personnel

Last Name Name Awards Contact
Reich Norbert O. Reich 1
Mikovits Judy Anne Mikovits 6
Johnson Paul H Johnson 5

12 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/07/04 - 07/31/05

DESCRIPTION (provided by applicant): There is now considerable evidence that DNA methylation, by silencing tumor suppressor and mis-match repair genes, has a major role in the causation and progression of cancer and is also involved in abnormal DNA methylation events following HIV (Human Immunodeficiency Virus) infection. In the past year, two p...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/04 - 01/31/05

DESCRIPTION (provided by applicant): The focus of this proposal is to develop drug candidates that inhibit DNA Adenine Methyltransferase (DAM) as a new class of antibiotics for the treatment of bacterial infection. Widespread antibiotic resistant pathogenic organisms create life-threatening conditions for patients in both hospital and community ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/20/03 - 07/31/04

DESCRIPTION (provided by applicant): There is now considerable evidence that DNA methylation, by silencing tumor suppressor and mis-match repair genes, has a major role in the causation and progression of cancer and is also involved in abnormal DNA methylation events following HIV (Human Immunodeficiency Virus) infection. In the past year, two p...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/20/03 - 07/31/04

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-91
Budget: 05/01/03 - 04/30/04

DESCRIPTION (provided by applicant): We propose to develop a new class of anticancer therapeutics based on inhibiting DNA cytosine methyltransferase (DNMT). Such compounds will form the basis for subsequent drug development, with potential applications to cancer ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 02/01/03 - 01/31/04

DESCRIPTION (provided by applicant): The focus of this proposal is to develop drug candidates that inhibit DNA Adenine Methyltransferase (DAM) as a new class of antibiotics for the treatment of bacterial infection. Widespread antibiotic resistant pathogenic organisms create life-threatening conditions for patients in both hospital and community ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-99-101
Budget: 08/26/02 - 06/30/03

DESCRIPTION: (provided by applicant) This grant will support development of new technology for high throughput analysis of methylation status in CpG islands, which is scalable to total genome characterization. This technology is capable of providing whole genome analysi...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PAR-01-105
Budget: 08/01/02 - 01/31/03

DESCRIPTION (provided by applicant): A high-throughput technology, termed DMS2 (DMS square) for Direct Microarray-based Screening of Differentially Methylated CpG Sites, has been developed for the discovery of abnormally methylated sites as cancer molecular markers. Combining the methylation specificity of restriction enzymes, the sensitivity of...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-91
Budget: 05/01/02 - 04/30/03

DESCRIPTION (provided by applicant): We propose to develop a new class of anticancer therapeutics based on inhibiting DNA cytosine methyltransferase (DNMT). Such compounds will form the basis for subsequent drug development, with potential applications to cancer ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/01 - 08/31/02

The primary objective is to discover and develop anti-cancer drugs that target the DNA methylation process. DNA methylation changes and abnormal epigenetic gene silencing correlate perfectly with the advancement of many types of cancer. An increased DNA methyltransferase activity during the progression of many cancers leads to the loss of expres...

Load More